SCHEMBL10458288

SCHEMBL10458288

FCCOc1ccc(I)cc1

nearest known ligand 0.52

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
APP P05067 12/20 0.52
ALDH1A1 P00352 1/20 0.47
GPR84 Q9NQS5 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18429635 0.88 APP (0.74) APP
SCHEMBL18429676 0.88 APP (0.74) APP
SCHEMBL10457449 0.87 APP (0.59) APPALDH1A1
SCHEMBL2802425 0.87 APP (0.57) APP
SCHEMBL4584910 0.81 TAAR1 (0.60) APPALDH1A1
SCHEMBL2996533 0.81 ALDH1A1 (0.60) APPALDH1A1GPR84
SCHEMBL15677357 0.80 APP (0.56) APP
SCHEMBL10458215 0.80 APP (0.53) APPALDH1A1
SCHEMBL2014873 0.79 APP (0.50) APPALDH1A1
SCHEMBL14870900 0.79 APP (0.50) APP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4960884-A Insecticides, nematocides, pesticides and miticides FMC CORPORATION (US) 1990-10-02 US claimed
EP-4665718-A1 SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF Apogee Pharmaceuticals, Inc. (CA) 2025-12-24 EP disclosed
US-12378231-B2 Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof APOGEE PHARMACEUTICALS, INC. (CA) 2025-08-05 US disclosed
US-20240294514-A1 SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF APOGEE PHARMACEUTICALS, INC. (CA) 2024-09-05 US disclosed
WO-2024168426-A1 SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF APOGEE PHARMACEUTICALS, INC. (CA) 2024-08-22 WO disclosed
WO-2017049080-A1 ANTIFUNGAL COMPOUND PROCESS VIAMET PHARMACEUTICALS, INC. (US) 2017-03-23 WO disclosed
US-7678819-B2 Acetylene derivatives and their use for binding and imaging amyloid plaques THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2010-03-16 US disclosed
US-20080166299-A1 Prevent accumulation of amyloid deposits TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2008-07-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080166299-A1 Prevent accumulation of amyloid deposits APP, IAPP, TTR APP 1/4885ALDH1A1 3939/4885GPR84 4665/4885
US-12378231-B2 Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof MGLL, PNLIP, LPL APP 133/4885ALDH1A1 530/4885GPR84 2892/4885
US-20240294514-A1 SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF MGLL, PNLIP, LPL APP 133/4885ALDH1A1 530/4885GPR84 2892/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.